Last updated: February 17, 2026
What is the scope of available market data and pricing for NDC 72888-0011?
NDC 72888-0011 corresponds to Sotyktu ( deucravacitinib ), developed by Bristol-Myers Squibb. As a first-in-class oral selective TYK2 inhibitor approved by the FDA in September 2022 for moderate-to-severe plaque psoriasis, its market analysis and pricing insights reflect recent market entry, competitive dynamics, and potential adoption trajectory.
What is the current market landscape for Sotyktu?
Approved Indications and Market Size
- Indication: Moderate-to-severe plaque psoriasis [1].
- Market size: Estimated US prevalence of psoriasis at 7.5 million patients, with approximately 3 million patients having moderate-to-severe disease [2].
- Addressable population: Based on recent sales data, approximately 1.2 million patients in the US are eligible for biologics and targeted oral therapies.
Competitive Environment
- Major competitors:
- Biologics like Humira (adalimumab), Cosentyx (secukinumab), and Stelara (ustekinumab).
- Other oral options like Otezla (apremilast) and Xeljanz (tofacitinib).
- Market penetration: As a new oral agent, Sotyktu aims for rapid adoption among patients seeking alternatives to injectable biologics.
Market Trends
- Growing preference for oral therapies due to convenience.
- Increasing shifts from biologics to targeted oral drugs.
- Rising awareness and physician familiarity with TYK2 inhibitors.
What are the pricing and reimbursement factors impacting Sotyktu?
List Price and Industry Pricing Trends
- Initial list price: Approximately $87,000 per year for Sotyktu, positioning it within the high-cost oral therapy segment [3].
| Drug Name |
Indication |
Estimated Annual Cost |
Notes |
| Sotyktu (deucravacitinib) |
Plaque psoriasis |
~$87,000 |
Launch pricing, subject to negotiations |
| Otezla (apremilast) |
Psoriasis, psoriatic arthritis |
~$33,000 |
Oral, lower price point |
| Taltz (ixekizumab) |
Psoriasis, psoriatic arthritis |
~$84,000 |
Biologic, similar price range |
Reimbursement Dynamics
- Managed care plans are expected to favor Sotyktu due to its oral administration.
- Cost negotiations may impact net prices and formulary access.
- Biosimilar and generic biologic entry may influence pricing pressures in the coming years.
What are projections for market growth and revenue?
Sales Forecasts
Analysts project Sotyktu could reach $350–$400 million in US sales by 2025 [4].
| Year |
US Sales Projection |
Comments |
| 2022 |
<$10 million |
Launch year, limited market penetration |
| 2023 |
~$100 million |
Early adoption, expanding prescriber base |
| 2024 |
~$250 million |
Increasing formulary inclusion, expanding patient pool |
| 2025 |
~$350–$400 million |
Mature market presence |
Key Factors Affecting Revenue
- Physician adoption rate.
- Insurance coverage and formulary inclusion.
- Competitive pricing and reimbursement strategies.
- Efficacy and safety profile compared to biologics and other oral agents.
What are the risks and uncertainties in market and price projections?
- Launch delays or regulatory hurdles.
- Competitive product development, especially biosimilars.
- Physician and patient acceptance.
- Potential safety signals impacting prescriptions.
- Price erosion resulting from payor negotiations and biosimilar entry.
What is the impact of potential regulatory or policy changes?
- Pricing reforms or caps could reduce maximum allowable charges.
- Expanded approvals for related indications may broaden market size.
- Policy changes favoring biosimilars could pressure Sotyktu pricing.
Key Takeaways
- Sotyktu’s initial list price is around $87,000 annually, targeting high-cost but expanding oral psoriasis therapies.
- Market size in the US exceeds 3 million eligible patients, with growth driven by patient and physician preferences for oral agents.
- Estimated US sales could reach $350–$400 million by 2025, dependent on adoption rates, reimbursement, and competitive dynamics.
- Key risks include biosimilar competition, formulary access, and regulatory updates.
FAQs
1. How does Sotyktu’s price compare to other psoriasis treatments?
It is significantly higher than oral options like Otezla but comparable to biologics such as Taltz, reflecting its novel mechanism and targeted therapy profile.
2. Will insurance companies cover Sotyktu at launch?
Most likely, coverage will depend on formulary status, clinical evidence, and negotiations; early access is often favorable for newly approved therapies.
3. How quickly can Sotyktu gain market share?
Initial adoption may be limited to specialty clinics; rapid growth depends on prescriber awareness, patient demand, and payer acceptance.
4. What factors could lower the drug’s price over time?
Entry of biosimilars, policy reforms, and increased competition typically exert downward pressure on list prices.
5. Are there indications beyond psoriasis where Sotyktu could be marketed?
Potential exists for expanded indications, such as psoriatic arthritis, which could further increase revenue potential.
References
[1] FDA Approval Announcement for Sotyktu, September 2022.
[2] American Academy of Dermatology Association: Psoriasis Prevalence Data.
[3] Industry reports on launch prices for new biologics and targeted therapies (2022).
[4] EvaluatePharma, Market Forecasts for Deucravacitinib (2023).
